What is the 13F Pro Quality Score for AXSM?

13F Pro ranks Axsome Therapeutics, Inc. (AXSM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AXSM's current score at https://13fpro.ai/research/AXSM (free sign-up required for the full ranking).

Where does 13F Pro source AXSM data?

All Axsome Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Axsome Therapeutics, Inc. files with the SEC under CIK 1579428. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AXSM in?

Axsome Therapeutics, Inc. (AXSM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AXSM research updated on 13F Pro?

AXSM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Axsome Therapeutics, Inc.(AXSM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1579428 AXSM stock profile & AI dashboard →

13F Pro Quality Score

36.6/100

Rank #2,091 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

92.4/100

Profitability

13.4/100

Balance Sheet

7.0/100

Earnings Quality

30.0/100

Free Cash Flow

16.0/100

Institutional Flow

75.8/100

Revenue Scale

40.6/100

Dilution Risk

12.7/100

AXSM Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Axsome Therapeutics, Inc. (AXSM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AXSM at 36.6/100 on a 32-signal composite quality model, placing it at rank #2,091 of 2,879 stocks — the bottom half of the AI-ranked universe. AXSM scores in the top quartile across revenue growth (92.4), institutional flow (75.8). Areas of concern include balance sheet strength (7.0) and profitability (13.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 12.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Axsome Therapeutics, Inc. reports quarterly revenue of $191.2M, net income of $-64.5M, an operating margin of -33.1%. Top institutional holders of AXSM by reported 13-F value include BlackRock,, VANGUARD PORTFOLIO MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. AXSM trades on the Nasdaq exchange and files with the SEC under CIK 1579428. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AXSM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Axsome Therapeutics, Inc. directly from SEC EDGAR. Axsome Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 8 and 88 since 2023, currently 36.6 — an improving long-term trajectory across 48 quarterly and live scoring snapshots.

✦

Fun facts about Axsome Therapeutics, Inc.

Quirks, history, and lore behind AXSM — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in New York City.
2
The Numbers
Revenue in the low hundreds of millions of dollars annually — a company still in its commercial adolescence, having only recently moved from pure R&D to actual product sales.
3
The History
Founded in the 2010s, it spent years quietly developing drugs targeting central nervous system disorders before finally winning hard-fought FDA approvals.
4
The Secret
Its pipeline focuses almost entirely on CNS conditions — think depression, narcolepsy, and Alzheimer's agitation — areas where Big Pharma largely gave up for decades.
5
The Lore
Its lead approved product, Auvelity, is a fast-acting oral antidepressant that works through a novel NMDA receptor mechanism — a totally different pathway than traditional SSRIs.
6
The Giveaway
With Auvelity for major depressive disorder and Sunosi in its portfolio, this company's ticker is practically a battle cry: AXSM.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$191.2M

Net Income

Q1 2026

$-64.5M

Free Cash Flow

Q1 2026

$-20.8M

Operating Margin

Q1 2026

-33.1%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+65.5% YoY

$638.5MFY 2025

FY20 —FY21 —FY24 $385.7MFY25 $638.5M

Net Income

+36.2% YoY

$-183.2MFY 2025

FY20 $-102.9MFY21 $-130.4MFY24 $-287.2MFY25 $-183.2M

Operating Income

+40.6% YoY

$-166.8MFY 2025

FY20 $-99.1MFY21 $-124.7MFY24 $-280.6MFY25 $-166.8M

EPS (Diluted)

+38.6% YoY

$-3.68FY 2025

FY20 $-2.77FY21 $-3.47FY24 $-5.99FY25 $-3.68

Total Assets

+21.3% YoY

$689.8MFY 2025

FY20 $186.1MFY21 $87.8MFY24 $568.5MFY25 $689.8M

Total Debt

+3.9% YoY

$187.7MFY 2025

FY20 $48.3MFY21 $49.1MFY24 $180.7MFY25 $187.7M

Op. Cash Flow

+27.3% YoY

$-93.4MFY 2025

FY20 $-78.5MFY21 $-108.2MFY24 $-128.4MFY25 $-93.4M

Metric	FY 2025	FY 2024	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	$638.5M +65.5%	$385.7M	—	—	—	—
Net Income	$-183.2M +36.2%	$-287.2M -120.3%	$-130.4M -26.7%	$-102.9M -50.6%	$-68.3M -120.7%	$-31.0M
Operating Income	$-166.8M +40.6%	$-280.6M -125.0%	$-124.7M -25.8%	$-99.1M -47.4%	$-67.2M -104.7%	$-32.8M
EPS (Diluted)	$-3.68 +38.6%	$-5.99 -72.6%	$-3.47 -25.3%	$-2.77	—	—
Total Assets	$689.8M +21.3%	$568.5M +547.6%	$87.8M -52.8%	$186.1M -15.6%	$220.5M +1334.1%	$15.4M
Total Debt	$187.7M +3.9%	$180.7M +268.1%	$49.1M +1.6%	$48.3M +142.4%	$19.9M +188.5%	$6.9M
Operating Cash Flow	$-93.4M +27.3%	$-128.4M -18.6%	$-108.2M -37.9%	$-78.5M -69.2%	$-46.4M -54.3%	$-30.1M

AI Insight: AXSM Financial Trends

Revenue growth accelerating despite persistent operating losses, but Q1 2026 shows margin deterioration and equity contraction.

• Revenue grew 119% from $87M (Q2 2024) to $191M (Q1 2026), with Q3 2025 marking first positive operating cash flow at $1M.

• Operating loss narrowed from $78M (Q2 2024) to $27M (Q4 2025), representing 65% improvement before Q1 2026 reversal to $63M.

• Total debt flat at $188M since Q2 2025 while equity declined 25% from $103M (Q2 2024) to $55M (Q1 2026).

⚠ Q1 2026 operating loss surged to $63M from $27M in Q4 2025—largest quarterly loss in 18 months despite flat revenue.

⚠ Equity down 39% to $55M from $88M peak (Q4 2025); debt-to-equity ratio deteriorating as losses persist.

AI Insight: AXSM Ratio Trends

Operating margin improved 71pp from Q2 2024 to Q4 2025, but Q1 2026 deteriorated sharply, signaling operational instability.

• Operating margin recovered from -89.5% in Q2 2024 to -13.8% in Q4 2025, showing 75.7pp improvement over 18 months.

• Q1 2026 OpMargin dropped to -33.1%, reversing Q4 2025 gains and reversing trajectory — worst quarter since Q1 2025.

• Debt-to-equity declined from 3.44x (TTM) to 2.13x in Q4 2025, improving leverage position before Q1 2026 reset to 3.44x.

⚠ Q1 2026 margin deterioration and negative ROA (-36.2%) suggest seasonal headwind or one-time cost; trend reversal critical to monitor.

⚠ ROIC remains deeply negative across all quarters (-39.1% to -97.2%), destroying shareholder value despite margin recovery headline.

Get alerted when AXSM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Axsome Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AXSM

BlackRock, Inc.
$661.3M3,912,844 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$347.9M2,058,170 sh
VANGUARD CAPITAL MANAGEMENT LLC
$327.5M1,937,752 sh
FMR LLC
$264.9M1,566,995 sh
Invesco Ltd.
$219.3M1,297,678 sh
GEODE CAPITAL MANAGEMENT, LLC
$196.6M1,162,981 sh
WELLINGTON MANAGEMENT GROUP LLP
$193.6M1,145,306 sh
Deep Track Capital, LP
$185.9M1,100,000 sh
STATE STREET CORP
$166.8M986,809 sh
Assenagon Asset Management S.A.
$146.4M865,958 sh

Fund	Value	Shares
BlackRock, Inc.	$661.3M	3,912,844
VANGUARD PORTFOLIO MANAGEMENT LLC	$347.9M	2,058,170
VANGUARD CAPITAL MANAGEMENT LLC	$327.5M	1,937,752
FMR LLC	$264.9M	1,566,995
Invesco Ltd.	$219.3M	1,297,678
GEODE CAPITAL MANAGEMENT, LLC	$196.6M	1,162,981
WELLINGTON MANAGEMENT GROUP LLP	$193.6M	1,145,306
Deep Track Capital, LP	$185.9M	1,100,000
STATE STREET CORP	$166.8M	986,809
Assenagon Asset Management S.A.	$146.4M	865,958

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AXSM on your watchlist

Track score changes the day Axsome Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AXSM a good stock to buy?

13F Pro's AI-powered analysis of Axsome Therapeutics, Inc. (AXSM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AXSM are available on the AXSM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own AXSM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AXSM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Axsome Therapeutics, Inc.'s investment landscape.